Search

Your search keyword '"Davila, Marco L"' showing total 582 results
Start Over Author "Davila, Marco L"
582 results on '"Davila, Marco L"'

2. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study

Author

Lee, Dae Hyun, Chandrasekhar, Sanjay, Jain, Michael D., Mhaskar, Rahul, Reid, Kayla, Lee, Sae Bom, Corallo, Salvatore, Hidalgo-Vargas, Melanie J., Kumar, Abhishek, Chavez, Julio, Shah, Bijal, Lazaryan, Aleksandr, Khimani, Farhad, Nishihori, Taiga, Bachmeier, Christina, Faramand, Rawan, Fradley, Michael G., Jeong, Daniel, Oliveira, Guilherme H., Locke, Frederick L., Davila, Marco L, and Alomar, Mohammed

Published
2023
Full Text
View/download PDF

3. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

Author

Stein-Thoeringer, Christoph K., Saini, Neeraj Y., Zamir, Eli, Blumenberg, Viktoria, Schubert, Maria-Luisa, Mor, Uria, Fante, Matthias A., Schmidt, Sabine, Hayase, Eiko, Hayase, Tomo, Rohrbach, Roman, Chang, Chia-Chi, McDaniel, Lauren, Flores, Ivonne, Gaiser, Rogier, Edinger, Matthias, Wolff, Daniel, Heidenreich, Martin, Strati, Paolo, Nair, Ranjit, Chihara, Dai, Fayad, Luis E., Ahmed, Sairah, Iyer, Swaminathan P., Steiner, Raphael E., Jain, Preetesh, Nastoupil, Loretta J., Westin, Jason, Arora, Reetakshi, Wang, Michael L., Turner, Joel, Menges, Meghan, Hidalgo-Vargas, Melanie, Reid, Kayla, Dreger, Peter, Schmitt, Anita, Müller-Tidow, Carsten, Locke, Frederick L., Davila, Marco L., Champlin, Richard E., Flowers, Christopher R., Shpall, Elizabeth J., Poeck, Hendrik, Neelapu, Sattva S., Schmitt, Michael, Subklewe, Marion, Jain, Michael D., Jenq, Robert R., and Elinav, Eran

Published
2023
Full Text
View/download PDF

4. JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Author

Pidala, Joseph, Holtan, Shernan G., Walton, Kelly, Kim, Jongphil, Cao, Biwei, Elmariah, Hany, Mishra, Asmita, Bejanyan, Nelli, Nishihori, Taiga, Khimani, Farhad, Perez, Lia, Faramand, Rawan G., Davila, Marco L., McSain, Shannon, Pleskow, Jordan, Baron, Jeffrey, Anasetti, Claudio, Moran Segura, Carlos, Weisdorf, Daniel J., Blazar, Bruce R., Miller, Jeffrey S., Bachanova, Veronika, El Jurdi, Najla, and Betts, Brian C.

Published
2024
Full Text
View/download PDF

6. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

Author

Maus, Marcela V, Alexander, Sara, Bishop, Michael R, Brudno, Jennifer N, Callahan, Colleen, Davila, Marco L, Diamonte, Claudia, Dietrich, Jorg, Fitzgerald, Julie C, Frigault, Matthew J, Fry, Terry J, Holter-Chakrabarty, Jennifer L, Komanduri, Krishna V, Lee, Daniel W, Locke, Frederick L, Maude, Shannon L, McCarthy, Philip L, Mead, Elena, Neelapu, Sattva S, Neilan, Tomas G, Santomasso, Bianca D, Shpall, Elizabeth J, Teachey, David T, Turtle, Cameron J, Whitehead, Tom, and Grupp, Stephan A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Pediatric, Immunization, Cancer, Biotechnology, Clinical Research, Patient Safety, Vaccine Related, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Drug-Related Side Effects and Adverse Reactions, Guidelines as Topic, Humans, Immunologic Factors, Immunotherapy, Retrospective Studies, adoptive, cell engineering, chimeric antigen, guidelines as topic, hematological neoplasms, immunotherapy, receptors, Oncology and carcinogenesis
Abstract

Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disease states, as 'living drugs,' their toxicity profiles, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), differ markedly from conventional cancer therapeutics. At the time of article preparation, the US Food and Drug Administration (FDA) has approved tisagenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel, all of which are IEC therapies based on genetically modified T cells engineered to express chimeric antigen receptors (CARs), and additional products are expected to reach marketing authorization soon and to enter clinical development in due course. As IEC therapies, especially CAR T cell therapies, enter more widespread clinical use, there is a need for clear, cohesive recommendations on toxicity management, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of common toxicities in the context of IEC treatment, including baseline laboratory parameters for monitoring, timing to onset, and pharmacological interventions, ultimately forming evidence- and consensus-based recommendations to assist medical professionals in decision-making and to improve outcomes for patients.

Published
2020

7. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial

Author

Sallman, David A, Kerre, Tessa, Havelange, Violaine, Poiré, Xavier, Lewalle, Philippe, Wang, Eunice S, Brayer, Jason B, Davila, Marco L, Moors, Ine, Machiels, Jean-Pascal, Awada, Ahmad, Alcantar-Orozco, Erik M, Borissova, Rossitza, Braun, Nathalie, Dheur, Marie-Sophie, Gilham, David E, Lonez, Caroline, Lehmann, Frédéric F, and Flament, Anne

Published
2023
Full Text
View/download PDF

8. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

Author

Logue, Jennifer M., Peres, Lauren C., Hashmi, Hamza, Colin-Leitzinger, Christelle M., Shrewsbury, Alexandria M., Hosoya, Hitomi, Gonzalez, Rebecca M., Copponex, Christina, Kottra, Krista H., Hovanky, Vanna, Sahaf, Bita, Patil, Sunita, Lazaryan, Aleksandr, Jain, Michael D., Baluch, Aliyah, Klinkova, Olga V., Bejanyan, Nelli, Faramand, Rawan G., Elmariah, Hany, Khimani, Farhad, Davila, Marco L., Mishra, Asmita, Blue, Brandon J., Grajales-Cruz, Ariel F., Castaneda Puglianini, Omar A., Liu, Hien D., Nishihori, Taiga, Freeman, Ciara L., Brayer, Jason B., Shain, Kenneth H., Baz, Rachid C., Locke, Frederick L., Alsina, Melissa, Sidana, Surbhi, and Hansen, Doris K.

Published
2022
Full Text
View/download PDF

10. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease

Author

Lazaryan, Aleksandr, Lee, Stephanie, Arora, Mukta, Kim, Jongphil, Betts, Brian Christopher, Khimani, Farhad, Nishihori, Taiga, Bejanyan, Nelli, Liu, Hien, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Gonzalez, Rebecca, Jain, Michael D., Davila, Marco L., Perez, Lia Elena, Mishra, Asmita, Perez Perez, Ariel, Balke, Karlie, Ayala, Ernesto, Ochoa, Leonel, Castaneda Puglianini, Omar, Faramand, Rawan, Alsina, Melissa, Elmariah, Hany, Nieder, Michael L., Fernandez, Hugo, Anasetti, Claudio, and Pidala, Joseph A.

Published
2022
Full Text
View/download PDF

12. VDJServer: A Cloud-Based Analysis Portal and Data Commons for Immune Repertoire Sequences and Rearrangements

Author

Christley, Scott, Scarborough, Walter, Salinas, Eddie, Rounds, William H, Toby, Inimary T, Fonner, John M, Levin, Mikhail K, Kim, Min, Mock, Stephen A, Jordan, Christopher, Ostmeyer, Jared, Buntzman, Adam, Rubelt, Florian, Davila, Marco L, Monson, Nancy L, Scheuermann, Richard H, and Cowell, Lindsay G

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Biomedical and Clinical Sciences, Genetics, Immunology, Bioengineering, Networking and Information Technology R&D (NITRD), Human Genome, Cancer, Biotechnology, 1.5 Resources and infrastructure (underpinning), Underpinning research, Animals, Cloud Computing, Computational Biology, Computing Methodologies, Genomics, Humans, Information Dissemination, Mice, Software, User-Computer Interface, VDJ Exons, Web Browser, Workflow, bioinformatics, cloud computing, Rep-seq, immune repertoire, B-cell receptor, T cell receptor, Medical Microbiology, Biochemistry and cell biology
Abstract

BackgroundRecent technological advances in immune repertoire sequencing have created tremendous potential for advancing our understanding of adaptive immune response dynamics in various states of health and disease. Immune repertoire sequencing produces large, highly complex data sets, however, which require specialized methods and software tools for their effective analysis and interpretation.ResultsVDJServer is a cloud-based analysis portal for immune repertoire sequence data that provide access to a suite of tools for a complete analysis workflow, including modules for preprocessing and quality control of sequence reads, V(D)J gene segment assignment, repertoire characterization, and repertoire comparison. VDJServer also provides sophisticated visualizations for exploratory analysis. It is accessible through a standard web browser via a graphical user interface designed for use by immunologists, clinicians, and bioinformatics researchers. VDJServer provides a data commons for public sharing of repertoire sequencing data, as well as private sharing of data between users. We describe the main functionality and architecture of VDJServer and demonstrate its capabilities with use cases from cancer immunology and autoimmunity.ConclusionVDJServer provides a complete analysis suite for human and mouse T-cell and B-cell receptor repertoire sequencing data. The combination of its user-friendly interface and high-performance computing allows large immune repertoire sequencing projects to be analyzed with no programming or software installation required. VDJServer is a web-accessible cloud platform that provides access through a graphical user interface to a data management infrastructure, a collection of analysis tools covering all steps in an analysis, and an infrastructure for sharing data along with workflows, results, and computational provenance. VDJServer is a free, publicly available, and open-source licensed resource.

Published
2018

13. Table S5 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

Author

Faramand, Rawan G., primary, Lee, Sae Bom, primary, Jain, Michael D., primary, Cao, Biwei, primary, Wang, Xuefeng, primary, Rejeski, Kai, primary, Subklewe, Marion, primary, Fahrmann, Johannes F., primary, Saini, Neeraj Y., primary, Hanash, Samir M., primary, Kang, Yun Pyo, primary, Chang, Darwin, primary, Rodriguez, Paolo C., primary, Dean, Erin A., primary, Nishihori, Taiga, primary, Shah, Bijal D., primary, Lazaryan, Aleksandr, primary, Chavez, Julio, primary, Khimani, Farhad, primary, Pinilla-Ibarz, Javier A., primary, Dam, Marian, primary, Reid, Kayla M., primary, Corallo, Salvatore A., primary, Menges, Meghan, primary, Hidalgo Vargas, Melanie, primary, Mandula, Jay K., primary, Holliday, Brian A., primary, Bachmeier, Christina A., primary, Speth, Kelly, primary, Song, Qinghua, primary, Mattie, Mike, primary, Locke, Frederick L., primary, and Davila, Marco L., primary

Published
2024
Full Text
View/download PDF

14. Data from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

Author

Faramand, Rawan G., primary, Lee, Sae Bom, primary, Jain, Michael D., primary, Cao, Biwei, primary, Wang, Xuefeng, primary, Rejeski, Kai, primary, Subklewe, Marion, primary, Fahrmann, Johannes F., primary, Saini, Neeraj Y., primary, Hanash, Samir M., primary, Kang, Yun Pyo, primary, Chang, Darwin, primary, Rodriguez, Paolo C., primary, Dean, Erin A., primary, Nishihori, Taiga, primary, Shah, Bijal D., primary, Lazaryan, Aleksandr, primary, Chavez, Julio, primary, Khimani, Farhad, primary, Pinilla-Ibarz, Javier A., primary, Dam, Marian, primary, Reid, Kayla M., primary, Corallo, Salvatore A., primary, Menges, Meghan, primary, Hidalgo Vargas, Melanie, primary, Mandula, Jay K., primary, Holliday, Brian A., primary, Bachmeier, Christina A., primary, Speth, Kelly, primary, Song, Qinghua, primary, Mattie, Mike, primary, Locke, Frederick L., primary, and Davila, Marco L., primary

Published
2024
Full Text
View/download PDF

15. Figure S2 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

Author

Faramand, Rawan G., primary, Lee, Sae Bom, primary, Jain, Michael D., primary, Cao, Biwei, primary, Wang, Xuefeng, primary, Rejeski, Kai, primary, Subklewe, Marion, primary, Fahrmann, Johannes F., primary, Saini, Neeraj Y., primary, Hanash, Samir M., primary, Kang, Yun Pyo, primary, Chang, Darwin, primary, Rodriguez, Paolo C., primary, Dean, Erin A., primary, Nishihori, Taiga, primary, Shah, Bijal D., primary, Lazaryan, Aleksandr, primary, Chavez, Julio, primary, Khimani, Farhad, primary, Pinilla-Ibarz, Javier A., primary, Dam, Marian, primary, Reid, Kayla M., primary, Corallo, Salvatore A., primary, Menges, Meghan, primary, Hidalgo Vargas, Melanie, primary, Mandula, Jay K., primary, Holliday, Brian A., primary, Bachmeier, Christina A., primary, Speth, Kelly, primary, Song, Qinghua, primary, Mattie, Mike, primary, Locke, Frederick L., primary, and Davila, Marco L., primary

Published
2024
Full Text
View/download PDF

16. Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

Author

Faramand, Rawan G., primary, Lee, Sae Bom, additional, Jain, Michael D., additional, Cao, Biwei, additional, Wang, Xuefeng, additional, Rejeski, Kai, additional, Subklewe, Marion, additional, Fahrmann, Johannes F., additional, Saini, Neeraj Y., additional, Hanash, Samir M., additional, Kang, Yun Pyo, additional, Chang, Darwin, additional, Rodriguez, Paolo C., additional, Dean, Erin A., additional, Nishihori, Taiga, additional, Shah, Bijal D., additional, Lazaryan, Aleksandr, additional, Chavez, Julio, additional, Khimani, Farhad, additional, Pinilla-Ibarz, Javier A., additional, Dam, Marian, additional, Reid, Kayla M., additional, Corallo, Salvatore A., additional, Menges, Meghan, additional, Hidalgo Vargas, Melanie, additional, Mandula, Jay K., additional, Holliday, Brian A., additional, Bachmeier, Christina A., additional, Speth, Kelly, additional, Song, Qinghua, additional, Mattie, Mike, additional, Locke, Frederick L., additional, and Davila, Marco L., additional

Published
2024
Full Text
View/download PDF

18. Abstract 10475: Serial Inflammatory Cytokine Levels Are Increased in Atrial Fibrillation After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Author

Lee, Dae H, Jain, Michael, Faramand, Rawan G, Reid, Kayla, Lee, Sae Bom, Corallo, Salvatore, Hidalgo-Vargas, Melanie, Kumar, Abhishek, Chandrasekhar, Sanjay, Chavez, Julio, Shah, Bijal, Lazaryan, Aleksandr, Khimani, Farhad, Nishihori, Taiga, Bachmeier, Christina, Locke, Frederick, Oliveira, Guilherme, Alomar, Mohammed, and Davila, Marco L

Published
2022
Full Text
View/download PDF

19. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation

Author

Bejanyan, Nelli, Pidala, Joseph A., Wang, Xuefeng, Thapa, Ram, Nishihori, Taiga, Elmariah, Hany, Lazaryan, Aleksandr, Khimani, Farhad, Davila, Marco L., Mishra, Asmita, Faramand, Rawan, Jain, Michael D., Ochoa, Leonel, Perez, Lia Elena, Liu, Hien, Alsina, Melissa, Kharfan-Dabaja, Mohamed A., Fernandez, Hugo, Nieder, Michael L., Locke, Frederick L., Anasetti, Claudio, and Ayala, Ernesto

Published
2021
Full Text
View/download PDF

23. Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease

Author

Shrestha, Bishwas, Walton, Kelly, Reff, Jordan, Sagatys, Elizabeth M., Tu, Nhan, Boucher, Justin, Li, Gongbo, Ghafoor, Tayyebb, Felices, Martin, Miller, Jeffrey S., Pidala, Joseph, Blazar, Bruce R., Anasetti, Claudio, Betts, Brian C., and Davila, Marco L.

Subjects
Stem Cells Inc., Antigens -- Health aspects, B cells -- Health aspects, Dendritic cells -- Health aspects, Hematopoietic stem cell transplantation -- Health aspects, Leukemia -- Prevention, T cells -- Health aspects, Health care industry
Abstract

Graft-versus-host disease (GVHD) remains an important cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT). For decades, GVHD prophylaxis has included calcineurin inhibitors, despite their incomplete efficacy and impairment of graft-versus-leukemia (GVL). Distinct from pharmacologic immune suppression, we have developed what we believe is a novel, human CD83-targeted chimeric antigen receptor (CAR) T cell for GVHD prevention. CD83 is expressed on allo-activated conventional [CD4.sup.+] T cells (Tconvs) and proinflammatory dendritic cells (DCs), which are both implicated in GVHD pathogenesis. Human CD83 CAR T cells eradicate pathogenic [CD83.sup.+] target cells, substantially increase the ratio of regulatory T cells (Tregs) to allo-activated Tconvs, and provide durable prevention of xenogeneic GVHD. CD83 CAR T cells are also capable of treating xenogeneic GVHD. We show that human acute myeloid leukemia (AML) expresses CD83 and that myeloid leukemia cell lines are readily killed by CD83 CAR T cells. Human CD83 CAR T cells are a promising cell-based approach to preventing 2 critical complications of allo-HCT--GVHD and relapse. Thus, the use of human CD83 CAR T cells for GVHD prevention and treatment, as well as for targeting [CD83.sup.+] AML, warrants clinical investigation., Introduction Allogeneic hematopoietic cell transplantation (allo-HCT) is a procedure performed with curative intent for high-risk hematologic malignancies and bone marrow failure syndromes. Annually, thousands of patients receive allo-HCT worldwide, and [...]

Published
2020
Full Text
View/download PDF

26. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis

Author

Wood, Anthony C., Perez, Ariel Perez, Arciola, Brian, Patel, Kedar, Johnson, Grace, DiMaggio, Elizabeth, Bachmeier, Christina A., Reid, Kayla, Carallo, Salvatore, Vargas, Melanie H., Faramand, Rawan, Chavez, Julio C., Shah, Bijal, Gaballa, Sameh, Khimani, Farhad, Elmariah, Hany, Nishihori, Taiga, Lazaryan, Aleksandr, Freeman, Ciara, Davila, Marco L., Locke, Frederick L., Mhaskar, Rahul, Bassil, Claude, and Jain, Michael D.

Published
2022
Full Text
View/download PDF

27. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion

Author

Rejeski, Kai, primary, Perez, Ariel, additional, Iacoboni, Gloria, additional, Blumenberg, Viktoria, additional, Bücklein, Veit L., additional, Völkl, Simon, additional, Penack, Olaf, additional, Albanyan, Omar, additional, Stock, Sophia, additional, Müller, Fabian, additional, Karschnia, Philipp, additional, Petrera, Agnese, additional, Reid, Kayla, additional, Faramand, Rawan, additional, Davila, Marco L., additional, Modi, Karnav, additional, Dean, Erin A., additional, Bachmeier, Christina, additional, von Bergwelt-Baildon, Michael, additional, Locke, Frederick L, additional, Bethge, Wolfgang, additional, Bullinger, Lars, additional, Mackensen, Andreas, additional, Barba, Pere, additional, Jain, Michael D., additional, and Subklewe, Marion, additional

Published
2023
Full Text
View/download PDF

28. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome

Author

Staedtke, Verena, Bai, Ren-Yuan, Kim, Kibem, Darvas, Martin, Davila, Marco L., Riggins, Gregory J., and Rothman, Paul B.

Subjects
Catecholamines -- Control, Cytokines -- Analysis, Immune response regulation -- Analysis, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Cytokine release syndrome (CRS) is a life-threatening complication of several new immunotherapies used to treat cancers and autoimmune diseases.sup.1-5. Here we report that atrial natriuretic peptide can protect mice from CRS induced by such agents by reducing the levels of circulating catecholamines. Catecholamines were found to orchestrate an immunodysregulation resulting from oncolytic bacteria and lipopolysaccharide through a self-amplifying loop in macrophages. Myeloid-specific deletion of tyrosine hydroxylase inhibited this circuit. Cytokine release induced by T-cell-activating therapeutic agents was also accompanied by a catecholamine surge and inhibition of catecholamine synthesis reduced cytokine release in vitro and in mice. Pharmacologic catecholamine blockade with metyrosine protected mice from lethal complications of CRS resulting from infections and various biotherapeutic agents including oncolytic bacteria, T-cell-targeting antibodies and CAR-T cells. Our study identifies catecholamines as an essential component of the cytokine release that can be modulated by specific blockers without impairing the therapeutic response.Atrial natriuretic peptide, an anti-inflammatory protein, can protect against cytokine release syndrome induced by therapeutic agents such as tumour-targeting bacteria and CAR-T cells by blocking catecholamine synthesis by macrophages., Author(s): Verena Staedtke [sup.1] [sup.2] , Ren-Yuan Bai [sup.3] , Kibem Kim [sup.1] , Martin Darvas [sup.4] , Marco L. Davila [sup.5] , Gregory J. Riggins [sup.3] , Paul B. [...]

Published
2018
Full Text
View/download PDF

29. Supplementary Data from CD28 Costimulatory Domain–Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function

Author

Boucher, Justin C., primary, Li, Gongbo, primary, Kotani, Hiroshi, primary, Cabral, Maria L., primary, Morrissey, Dylan, primary, Lee, Sae Bom, primary, Spitler, Kristen, primary, Beatty, Nolan J., primary, Cervantes, Estelle V., primary, Shrestha, Bishwas, primary, Yu, Bin, primary, Kazi, Aslamuzzaman, primary, Wang, Xuefeng, primary, Sebti, Said M., primary, and Davila, Marco L., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma

Author

Saini, Neeraj Y., primary, Swoboda, David M., primary, Greenbaum, Uri, primary, Ma, Junsheng, primary, Patel, Romil D., primary, Devashish, Kartik, primary, Das, Kaberi, primary, Tanner, Mark R., primary, Strati, Paolo, primary, Nair, Ranjit, primary, Fayad, Luis, primary, Ahmed, Sairah, primary, Lee, Hun Ju, primary, Iyer, Swaminathan P., primary, Steiner, Raphael, primary, Jain, Nitin, primary, Nastoupil, Loretta, primary, Loghavi, Sanam, primary, Tang, Guilin, primary, Bassett, Roland L., primary, Jain, Preetesh, primary, Wang, Michael, primary, Westin, Jason R., primary, Green, Michael R., primary, Sallman, David A., primary, Padron, Eric, primary, Davila, Marco L., primary, Locke, Frederick L., primary, Champlin, Richard E., primary, Garcia-Manero, Guillermo, primary, Shpall, Elizabeth J., primary, Kebriaei, Partow, primary, Flowers, Christopher R., primary, Jain, Michael D., primary, Wang, Feng, primary, Futreal, Andrew P., primary, Gillis, Nancy, primary, Neelapu, Sattva S., primary, and Takahashi, Koichi, primary

Published
2023
Full Text
View/download PDF

31. Data from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma

Author

Saini, Neeraj Y., primary, Swoboda, David M., primary, Greenbaum, Uri, primary, Ma, Junsheng, primary, Patel, Romil D., primary, Devashish, Kartik, primary, Das, Kaberi, primary, Tanner, Mark R., primary, Strati, Paolo, primary, Nair, Ranjit, primary, Fayad, Luis, primary, Ahmed, Sairah, primary, Lee, Hun Ju, primary, Iyer, Swaminathan P., primary, Steiner, Raphael, primary, Jain, Nitin, primary, Nastoupil, Loretta, primary, Loghavi, Sanam, primary, Tang, Guilin, primary, Bassett, Roland L., primary, Jain, Preetesh, primary, Wang, Michael, primary, Westin, Jason R., primary, Green, Michael R., primary, Sallman, David A., primary, Padron, Eric, primary, Davila, Marco L., primary, Locke, Frederick L., primary, Champlin, Richard E., primary, Garcia-Manero, Guillermo, primary, Shpall, Elizabeth J., primary, Kebriaei, Partow, primary, Flowers, Christopher R., primary, Jain, Michael D., primary, Wang, Feng, primary, Futreal, Andrew P., primary, Gillis, Nancy, primary, Neelapu, Sattva S., primary, and Takahashi, Koichi, primary

Published
2023
Full Text
View/download PDF

32. Data from CD28 Costimulatory Domain–Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function

Author

Boucher, Justin C., primary, Li, Gongbo, primary, Kotani, Hiroshi, primary, Cabral, Maria L., primary, Morrissey, Dylan, primary, Lee, Sae Bom, primary, Spitler, Kristen, primary, Beatty, Nolan J., primary, Cervantes, Estelle V., primary, Shrestha, Bishwas, primary, Yu, Bin, primary, Kazi, Aslamuzzaman, primary, Wang, Xuefeng, primary, Sebti, Said M., primary, and Davila, Marco L., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure S2 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality

Author

Holtan, Shernan G., primary, Savid-Frontera, Constanza, primary, Walton, Kelly, primary, Eaton, Anne A., primary, Demorest, Connor, primary, Hoeschen, Andrea, primary, Zhang, Ling, primary, Reid, Kayla, primary, Kurian, Tony, primary, Sayegh, Zena, primary, Julia, Estefania, primary, Maakaron, Joseph, primary, Bachanova, Veronika, primary, Jurdi, Najla El, primary, MacMillan, Margaret L., primary, Weisdorf, Daniel J., primary, Felices, Martin, primary, Miller, Jeffrey S., primary, Blazar, Bruce R., primary, Davila, Marco L., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table S1 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality

Author

Holtan, Shernan G., primary, Savid-Frontera, Constanza, primary, Walton, Kelly, primary, Eaton, Anne A., primary, Demorest, Connor, primary, Hoeschen, Andrea, primary, Zhang, Ling, primary, Reid, Kayla, primary, Kurian, Tony, primary, Sayegh, Zena, primary, Julia, Estefania, primary, Maakaron, Joseph, primary, Bachanova, Veronika, primary, Jurdi, Najla El, primary, MacMillan, Margaret L., primary, Weisdorf, Daniel J., primary, Felices, Martin, primary, Miller, Jeffrey S., primary, Blazar, Bruce R., primary, Davila, Marco L., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

38. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma

Author

Mirza, Abu-Sayeef, Kumar, Ambuj, Hashmi, Hamza, Garcia, Franco, Logothetis, Constantine N., Darwin, Alicia, Faramand, Rawan, Reid, Kayla, Bachmeier, Christina, Chavez, Julio C., Shah, Bijal, Pinilla-Ibarz, Javier, Khimani, Farhad, Lazaryan, Aleksandr, Liu, Hien, Davila, Marco L., Nishihori, Taiga, Locke, Frederick L., and Jain, Michael D.

Published
2021
Full Text
View/download PDF

39. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Author

Hansen, Doris K., Kim, Jongphil, Thompson, Zachary, Hussaini, Mohammad, Nishihori, Taiga, Ahmad, Anam, Elmariah, Hany, Faramand, Rawan, Mishra, Asmita, Davila, Marco L., Khimani, Farhad, Lazaryan, Aleksandr, Sallman, David, Liu, Hien, Perez, Lia E., Fernandez, Hugo, Nieder, Michael L., Lancet, Jeffrey E., Pidala, Joseph A., Anasetti, Claudio, and Bejanyan, Nelli

Published
2021
Full Text
View/download PDF

40. Figure S1 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Author

Faramand, Rawan, primary, Jain, Michael, primary, Staedtke, Verena, primary, Kotani, Hiroshi, primary, Bai, Renyuan, primary, Reid, Kayla, primary, Lee, Sae Bom, primary, Spitler, Kristen, primary, Wang, Xuefeng, primary, Cao, Biwei, primary, Pinilla, Javier, primary, Lazaryan, Aleksander, primary, Khimani, Farhad, primary, Shah, Bijal, primary, Chavez, Julio C., primary, Nishihori, Taiga, primary, Mishra, Asmita, primary, Mullinax, John, primary, Gonzalez, Ricardo, primary, Hussaini, Mohammad, primary, Dam, Marian, primary, Brandjes, Brigett D., primary, Bachmeier, Christina A., primary, Anasetti, Claudio, primary, Locke, Frederick L., primary, and Davila, Marco L., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table 8 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 2 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 3 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 2 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Table 3 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table 4 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 1 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

48. Extended Methods from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 6 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Table 7 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results